1. Ecto-5′-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells
   Lei Song et al, 2017, Oncotarget CrossRef
2. Targeting immunosuppressive adenosine in cancer
   Dipti Vijayan et al, 2017, Nature Reviews Cancer CrossRef
3. The crossroads of adenosinergic pathway and epithelial-mesenchymal plasticity in cancer
   Isabele Cristiana Iser et al, 2022, Seminars in Cancer Biology CrossRef
4. Towards individualized therapy for metastatic renal cell carcinoma
   Ritesh R. Kotecha et al, 2019, Nature Reviews Clinical Oncology CrossRef
5. Loss of CD73 shifts transforming growth factor-β1 (TGF-β1) from tumor suppressor to promoter in endometrial cancer
   Katherine C. Kurnit et al, 2021, Cancer Letters CrossRef
6. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival
   Takao Kamai et al, 2021, Cancer Immunology, Immunotherapy CrossRef
7. The role of extracellular-5′-nucleotidase/CD73 in glioma peritumoural brain edema
   Bo Wang et al, 2016, Neurological Sciences CrossRef
8. The Immunobiology of Kidney Cancer
   Charles G. Drake et al, 2018, Journal of Clinical Oncology CrossRef
9. Targeting the CD73-adenosine axis in immuno-oncology
   David Allard et al, 2019, Immunology Letters CrossRef
10. Adenosine Pathway in Genitourinary Malignancies: A Promising Immunotherapeutic Target
    Sumit Dey et al, 2022, Biomedical Translational Research CrossRef
11. CD73–adenosine: a next-generation target in immuno-oncology
    David Allard et al, 2016, Immunotherapy CrossRef
12. CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche
    Giulia Bertolini et al, 2022, International Journal of Molecular Sciences CrossRef
13. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
    Paul A. Beavis et al, 2017, Journal of Clinical Investigation CrossRef
14. Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features
    Dai Takamatsu et al, 2023, Pathology - Research and Practice CrossRef
15. NT5E inhibition suppresses the growth of sunitinib‐resistant cells and EMT course and AKT/GSK‐3β signaling pathway in renal cell cancer
    Dan Peng et al, 2019, IUBMB Life CrossRef
16. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
    Lauren Giuffrida et al, 2021, Nature Communications CrossRef
17. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function
    Rui Jin et al, 2020, Molecular Cancer Therapeutics CrossRef
18. Ectonucleotidase inhibitors: a patent review (2011-2016)
    Mariya Al-Rashida et al, 2017, Expert Opinion on Therapeutic Patents CrossRef
19. Therapeutic Efficacy of Delta-Like Ligand 4 Gene Vaccine Overexpression on Liver Cancer in Mice
    Yi Yu et al, 2020, Technology in Cancer Research & Treatment CrossRef
20. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
    Abhishek Tripathi et al, 2020, Journal for ImmunoTherapy of Cancer CrossRef
21. Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?
    Geoffrey Alan Watson et al, 2020, British Journal of Clinical Pharmacology CrossRef
22. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers
    Tao Jiang et al, 2018, BMC Cancer CrossRef
23. Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer
    Thomas Powles et al, 2018, Journal of Clinical Oncology CrossRef
24. Prognostic significance of NT5E/CD73 in neuroblastoma and its function in CSC stemness maintenance
    Drishti Jain et al, 2021, Cell Biology and Toxicology CrossRef
25. Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Shunsuke Kondo et al, 2022, International Journal of Clinical Oncology CrossRef
26. Targeting the adenosine pathway for cancer immunotherapy
    Akil Hammami et al, 2019, Seminars in Immunology CrossRef